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Introduction {#sec005}
============

Lung cancer is the leading cause of cancer-related death worldwide \[[@pone.0120852.ref001]\], as well as in Taiwan. To improve the survival for advanced lung adenocarcinoma, strategies to target driver gene alterations are important and currently under intensive investigation.

Several molecular alterations are known to be involved in tumorigenesis of lung adenocarcinoma, such as *epidermal growth factor receptor (EGFR)*, *Kirsten rat sarcoma viral oncogene homolog (KRAS)*, *v-raf murine sarcoma viral oncogene homolog B (BRAF)*, *human epidermal growth factor receptor 2 (HER2)*, and *echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK)* fusion mutations. Mutations in these genes are responsible for both the initiation and maintenance of lung adenocarcinoma \[[@pone.0120852.ref002]\]. By understanding the biological functions of these driver genes, it may be possible to develop specific therapies for lung cancer with known driver gene mutations.

Recently, Kris et al. demonstrated that patients with an oncogenic driver mutation who received the corresponding targeted therapy had a significantly longer survival time than those with a driver mutation who did not receive the targeted therapy and those without a driver mutation \[[@pone.0120852.ref003]\]. In comparison with chemotherapy, EGFR-tyrosine kinase inhibitors (TKI), including gefitinib, erlotinib and afatinib, have provided a better outcome and quality of life for patients with advanced *EGFR*-mutant non-small cell lung cancer (NSCLC) and have become one of the standard first line therapies \[[@pone.0120852.ref004]--[@pone.0120852.ref006]\]. Similar efficacy was observed in *EML4-ALK* positive lung cancer patients treated with crizotinib and second-generation ALK inhibitors \[[@pone.0120852.ref007],[@pone.0120852.ref008]\].

Many drugs are available now and more will be developed for patients with specific driver gene mutations. Therefore, we decided to conduct a prospective study in five medical centers in Taiwan to explore the incidence of driver gene mutations and to define subgroups of patients in whom candidate driver gene alterations are enriched. Analyses of five driver genes, including *EGFR*, *KRAS*, *BRAF*, *HER2* and *EML4-ALK*, were performed in patients with treatment naïve lung adenocarcinoma.

Materials and Methods {#sec006}
=====================

Patients {#sec007}
--------

This multicenter prospective observational study was conducted in five medical centers in Taiwan, including Taichung Veterans General Hospital, National Taiwan University Hospital, China Medical University Hospital, Chung Shan University Hospital and Taichung Tzu Chi Hospital. To be eligible for the study, patients were required to have treatment-naïve and pathologically confirmed lung adenocarcinoma and available tumor specimens for genetic analysis. Patients were excluded if they had lung cancer with histology other than adenocarcinoma, including those with carcinoma not otherwise specified (NOS), or other active malignancy. This study was approved by the Institutional Review Board of the participating institutes, including, Institutional Review Board of Taichung Veterans General Hospital (IRB No. C08197), National Taiwan University Hospital Research Ethics Committee (IRB No. 201111039RIC), Institutional Review Board of Chung Shan Medical University Hospital (IRB No. CS12022), China Medical University and Hospital Research Ethics Committee (IRB No. DMR100-IRB-284\[CR-2\]) and Taichung Tzu Chi Hospital Research Ethics Committee (IRB No. REC102--7). Written informed consents for genetic testing and clinical data records were obtained from all patients.

Identification of driver mutations {#sec008}
----------------------------------

Five oncogenic drivers, including *EGFR*, *KRAS*, *BRAF*, *HER2* and *EML4-ALK*, were tested. *EGFR*, *KRAS*, *BRAF* and *HER2* mutations were assessed by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) since August 2011. *EML4-ALK* translocation was tested by Ventana method in patients with *EGFR*-wild type lung adenocarcinoma from July 2013. All the tests were performed by ISO15189-certified TR6 Pharmacogenomics Lab (PGL), National Research Program for Biopharmaceuticals (NRPB), the National Center of Excellence for Clinical Trial and Research of NTUH.

Tumor specimens were procured for *EGFR*, *KRAS*, *BRAF* and *HER2* mutation analyses as previously described \[[@pone.0120852.ref009]\]. Briefly, DNA was extracted from the tumors using a QIAmp DNA Mini kit (Qiagen, Valencia, CA) following the manufacturer's protocol. The genetic alterations of *EGFR*, *KRAS*, *BRAF* and *HER2* were detected by MALDI-TOF MS based on the methods used in our previous reports with modifications \[[@pone.0120852.ref010],[@pone.0120852.ref011]\]. Briefly, we expanded the multiplex gene-testing panel to include *EGFR*, *KRAS*, *BRAF* and *HER2* genes. We performed the analysis according to manufacturer's protocol for MassARRAY system (Sequenom, San Diego, CA). In the biochemical reaction, polymerase chain reaction (PCR) followed by single nucleotide extension was performed by using primers and corresponding detection probes to amplify the region containing each target mutation. After SpectroClean Resin clean up, samples were loaded onto the matrix of SpectroCHIP by Nanodispenser (Matrix) and then analyzed by Bruker Autoflex MALDI-TOF MS. Data were collected and analyzed by Typer 4 software (Sequenom, San Diego, CA). The PCR primers and probes used in the present study were summarized in [S1 Table](#pone.0120852.s001){ref-type="supplementary-material"}.

Because *EGFR* mutations and *EML4-ALK* translocations are almost mutually exclusive \[[@pone.0120852.ref012]\], assessment of *EML4-ALK* translocations was only performed in patients with *EGFR*-wild type lung adenocarcinoma in this project by Ventana method \[[@pone.0120852.ref013]\]. Briefly, the assay (Ventana IHC, Ventana, Tucson, AZ) was a fully automated IHC assay developed by Ventana, using the pre-diluted Ventana anti-ALK (D5F3) Rabbit monoclonal primary antibody, together with the Optiview DAB IHC detection kit and Optiview Amplification kit on the Benchmark XT stainer. Each specimen was also stained with a matched Rabbit Monoclonal Negative Control Immunoglobulin antibody. The manufacture's scoring algorithm was a binary scoring system (positive or negative for ALK status), which we adopted for evaluating the staining results. Neoplastic cells labeled with the ALK IHC assay were evaluated for presence or absence of the DAB signal. Presence of strong granular cytoplasmic staining in tumor cells (any percentage of positive tumor cells) was deemed to be ALK positive, while absence of strong granular cytoplasmic staining in tumor cells was deemed to be ALK negative.

Data records and response evaluation {#sec009}
------------------------------------

Activating mutation of *EGFR* gene is the most common genetic alteration in lung adenocarcinoma in East Asians \[[@pone.0120852.ref014]\]. Therefore, in addition to exploration of the incidence of driver mutations, we also evaluated the efficacy of EGFR-TKI in patients with *EGFR*-mutant lung adenocarcinoma. Clinical data for analysis included patients' age, gender, Eastern Cooperative Oncology Group performance status (ECOG PS), tumor stage and smoking status. TNM (tumor, node, and metastases) staging was done according to the 7th edition of the American Joint Committee for Cancer (AJCC) staging system \[[@pone.0120852.ref015]\]. Chest computed tomographies (CT), including the liver and adrenal glands, and other required imaging studies for response evaluation were reviewed by two chest physicians. Unidimensional measurements as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 were used in this study \[[@pone.0120852.ref016]\].

Statistical methods {#sec010}
-------------------

Univariate analyses by Fisher's exact test and Pearson Chi-square test were conducted on the frequency of five oncogenic drivers and on the objective response rate (ORR) and disease control rate (DCR) of EGFR-TKI therapy to evaluate the effects of clinical factors relating to patient and disease characteristics. Multivariate analyses of ORR and DCR were performed using logistic regression model. The Kaplan---Meier method was used to estimate progression-free survival (PFS) and overall survival (OS). Differences in survival time were analyzed using the log-rank test. Multivariate analyses of PFS and OS were performed using Cox proportional hazard model. All statistical tests were done with SPSS 15.0 (SPSS, Chicago, IL). Two-tailed tests and p values \<0.05 for significance were used.

Results {#sec011}
=======

Patient characteristics {#sec012}
-----------------------

From August 2011 to November 2013, a total of 1772 patients with treatment-naïve lung adenocarcinoma were enrolled as Cohort 1 for *EGFR*, *KRAS*, *BRAF* and *HER2* genetic analyses. With the development of Ventana method in July 2013 and the availability of tumor tissues, *EML4-ALK* translocation testing was performed in total 295 patients with *EGFR*-wild type lung adenocarcinoma, who were enrolled as Cohort 2. The baseline characteristics are shown in [Table 1](#pone.0120852.t001){ref-type="table"}. Briefly, in Cohort 1, the median age was 58 years (range 21--100), 821 patients (46.3%) were male, 1179 patients (66.5%) were non-smokers and 1248 patients (70.4%) had advanced stage diseases (stage IIIb or IV). In Cohort 2, the median age was 61 yeas (range 21--100), 150 patients (50.8%) were male, 177 patients (60.0%) were non-smokers and 198 patients (67.1%) had advanced stage diseases.

10.1371/journal.pone.0120852.t001

###### Characteristics and demographic data.

![](pone.0120852.t001){#pone.0120852.t001g}

  Characteristics                  Cohort 1[\*](#t001fn001){ref-type="table-fn"}   Cohort 2[\*\*](#t001fn002){ref-type="table-fn"}
  -------------------------------- ----------------------------------------------- -------------------------------------------------
  Age (years), median (range)      58 (21--100)                                    61 (21--100)
  Gender                                                                           
   Male, n (%)                     821 (46.3)                                      150 (50.8)
   Female, n (%)                   951 (53.7)                                      145 (49.2)
  Smoking status                                                                   
   Non-smokers, n (%)              1179 (66.5)                                     177 (60.0)
   Current/former smokers, n (%)   593 (33.5)                                      118 (40.0)
  Stage, n (%)                                                                     
   I                               290 (16.4)                                      49 (16.6)
   II                              81 (4.6)                                        18 (6.1)
   IIIa                            141 (8.0)                                       29 (9.8)
   IIIb                            121 (6.8)                                       17 (5.8)
   IV                              1127 (63.6)                                     181 (61.4)
   N/A                             12 (0.6)                                        1 (0.3)

\*Cohort 1: lung adenocarcinoma.

\*\*Cohort 2: epidermal growth factor receptor-wild type lung adenocarcinoma.

N/A, not applicable.

Incidence of five oncogenic drivers {#sec013}
-----------------------------------

The oncogenic driver mutations detected in the present study are summarized in [Table 2](#pone.0120852.t002){ref-type="table"}. The incidence of five driver gene mutations is shown in [Fig. 1](#pone.0120852.g001){ref-type="fig"} and [Table 2](#pone.0120852.t002){ref-type="table"}. In the Cohort 1 analysis, 987 of 1772 lung adenocarcinoma patients (55.7%) harbored activated *EGFR* mutations, which accounted for the majority of diver gene mutations. Mutations in *KRAS*, *HER2* and *BRAF* genes were identified in 93 (5.2%), 36 (2.0%) and 12 (0.7%) patients, respectively. A total of 651 patients (36.7%) had no detectable driver gene mutation. Majority of the genetic alterations were mutually exclusive, except for co-mutations in seven (0.4%) patients (3 with *EGFR* and *KRAS* mutations, 3 with *EGFR* and *HER2* mutations and 1 with *KRAS* and *BRAF* mutations). In the Cohort 2 analysis, 29 of 295 patients with *EGFR*-wild type lung adenocarcinoma (9.8%) were found to have *EML4-ALK* translocation and none of them harbored other driver gene mutations.

![Spectrum of genetic alterations among patients with lung adenocarcinoma.](pone.0120852.g001){#pone.0120852.g001}

10.1371/journal.pone.0120852.t002

###### Characteristics of genetic alterations assessed in the present study.

![](pone.0120852.t002){#pone.0120852.t002g}

  Gene[\*](#t002fn002){ref-type="table-fn"}   Exon/Domain   Patient No.   Assessed genetic alterations
  ------------------------------------------- ------------- ------------- -------------------------------------------
  *EGFR*                                      Exon 18       18            E709A, E709G, E709V
                                                                          G719A, G719C, G719N, G719S
                                              Exon 19       434           E746-A750del, E746-T751\>A,
                                                                          E746-S752\>V, L747-A750\>P, L747-T751\>P,
                                                                          L747-S752del, L747-T751del, L747-P753\>S,
                                                                          E746-T751\>I, E746-T751del, E746-S752\>A,
                                                                          E746-S752\>D, L747-A750\>P, L747-T751\>Q,
                                                                          L747-E749del, L747-P753\>Q, L747-T751\>S
                                              Exon 20       3             T790M, S768I
                                              Exon 21       483           L858R, L858Q, L861Q
                                              Exon 18--21   49            Complex mutations
  *KRAS*                                      Codon 12      89            G12S, G12R, G12C, G12D, G12A, G12V
                                              Codon 13      4             G13S, G13C, G13R, G13D, G13V, G13A
  *HER2*                                      Exon 20       36            A775-G776insYVMA
  *BRAF*                                      Exon 15       12            V600E
  *ALK*                                       N/A           29            *EML4-ALK* translocation

EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; EML4, echinoderm microtubule-associated protein like 4.

\*Cohort 1 (1772 patients with lung adenocarcinoma) testing of *EGFR*, *KRAS*, *HER2* and *BRAF* mutations and cohort 2 (295 patients with *EGFR*-wild type lung adenocarcinoma) testing of *EML4-ALK* translocation.

The detail of *EGFR* mutations is depicted in [Fig. 2](#pone.0120852.g002){ref-type="fig"}. A total of 1037 *EGFR* mutations were detected in 987 patients, including 49 patients (5.0%) who harbored complex mutations. Exon 19 in-frame deletions (44.8%) and exon 21 L858R (47.9%) were the major types of *EGFR* mutations. Furthermore, a total of 28 patients had primary exon 20 T790M mutation in the treatment-naïve tumor samples, mainly as part of complex mutations.

![Epidermal growth factor receptor (EGFR) mutation spectrum among patients with EGFR-mutant lung adenocarcinoma (complex mutations are counted as separated mutation types here).](pone.0120852.g002){#pone.0120852.g002}

Association between patient characteristics and driver gene mutations {#sec014}
---------------------------------------------------------------------

The analysis of association between patient characteristics and driver gene mutations is shown in [Table 3](#pone.0120852.t003){ref-type="table"}. For *EGFR* mutations, a significantly higher mutation rate was noted in female then in male patients (65.2 vs. 44.7%, P \< 0.001) and in non-smokers then in smokers (63.9 vs. 39.5%, P \< 0.001). Neither age nor tumor stage was significantly correlated with *EGFR* mutation.

10.1371/journal.pone.0120852.t003

###### Univariate analysis of genetic alterations and clinical characteristics.

![](pone.0120852.t003){#pone.0120852.t003g}

                                                        *EGFR* [\*](#t003fn002){ref-type="table-fn"}   *KRAS* [\*](#t003fn002){ref-type="table-fn"}   *HER2* [\*](#t003fn002){ref-type="table-fn"}   *BRAF* [\*](#t003fn002){ref-type="table-fn"}   *ALK* [\*\*](#t003fn003){ref-type="table-fn"}                                         
  ----------------------------------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ----------------------------------------------- ------- --------- ------- ----------- -------
  Age (years)                                                                                          0.501                                                                                         0.200                                                                                          0.502             0.777               0.002
   ≤ 65                                                 536 (55.0)                                                                                    45 (4.6)                                                                                      22 (2.3)                                                6 (0.6)           25 (14.0)   
   \> 65                                                451 (56.6)                                                                                    48 (6.0)                                                                                      14 (1.8)                                                6 (0.8)           4 (3.4)     
  Gender                                                                                               \<0.001                                                                                       \<0.001                                                                                        0.312             0.781               0.331
   Male                                                 367 (44.7)                                                                                    76 (9.3)                                                                                      20 (2.4)                                                5 (0.6)           12 (8.0)    
   Female                                               620 (65.2)                                                                                    17 (1.8)                                                                                      16 (1.7)                                                7 (0.7)           17 (11.7)   
  Smoking status                                                                                       \<0.001                                                                                       \<0.001                                                                                        1.000             1.000               0.167
   Non-smokers                                          753 (63.9)                                                                                    20 (1.7)                                                                                      24 (2.0)                                                8 (0.7)           21 (11.9)   
   Current/former smokers                               234 (39.5)                                                                                    73 (12.3)                                                                                     12 (2.0)                                                4 (0.7)           8 (6.8)     
  Stage, n (%)[^\#^](#t003fn004){ref-type="table-fn"}                                                  0.187                                                                                         1.000                                                                                          0.015             0.754               0.837
   I-IIIa                                               298 (58.2)                                                                                    27 (5.3)                                                                                      4 (0.8)                                                 4 (0.9)           10 (10.4)   
   IIIb-IV                                              682 (54.6)                                                                                    66 (5.3)                                                                                      32 (2.6)                                                8 (0.6)           19 (9.6)    

EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.

\*Cohort 1 (1772 patients with lung adenocarcinoma) testing of *EGFR*, *KRAS*, *HER2* and *BRAF* mutations.

\*\*Cohort 2 (295 patients with *EGFR*-wild type lung adenocarcinoma) testing of *EML4-ALK* translocation.

^\#^Exclude 12 patients of cohort 1 and 1 patients of cohort 2 with incomplete data on tumor staging For *KRAS* mutations, a significantly higher mutation rate was noted in male then in female patients (9.3 vs. 1.8%, P \< 0.001) and in smokers then in non-smokers (12.3 vs. 1.7%, P \< 0.001). Neither age nor tumor stage were correlated with *KRAS* mutation. For *HER2* mutations, patients with more advanced diseases were associated with a higher mutation rate (2.6% in stage IIIb-IV vs. 0.8% in stage I-IIIa, P = 0.015). For *BRAF* mutation, there was no significant association between patient characteristics and the mutation rate.

In the Cohort 2 analysis, age was the only factor that correlated significantly with *EML4-ALK* translocation and patients with younger age (≤ 65 years) had a higher mutation rate than patients aged more than 65 years (14.0 vs. 3.4%, P = 0.002). Moreover, we observed a trend toward a higher mutation rate in non-smokers compared with smokers (11.9 vs. 6.8%) but the trend did not reach a level of significance (P = 0.167). Neither age nor tumor stage was correlated significantly with *EML4-ALK* translocation.

Efficacy of EGFR-TKI in EGFR-mutant lung adenocarcinoma {#sec015}
-------------------------------------------------------

In total, 352 patients who had *EGFR*-mutations and lesions that could be measured for treatment responses received EGFR-TKI therapy as the first line treatment (336 with gefitinib and 16 with erlotinib). The drug prescribed was chosen by the physicians in charge. Three patients achieved complete response, 203 patients achieved partial response, 95 patients had stable disease and 51 patients had progressive disease. The ORR and DCR were 58.5% and 85.5%, respectively. Univariate analyses of ORR and DCR are shown in [Table 4](#pone.0120852.t004){ref-type="table"}. Patients with exon 19 deletions were associated with a higher ORR than those with L858R and other uncommon mutations (68.2 vs. 51.2 vs. 48.0%, P = 0.004). No other factors correlated significantly with ORR. In DCR analysis, females, non-smokers, patients with better ECOG PS (0--1) and those with exon 19 deletions were associated with a significantly higher DCR (P = 0.001, 0.013, \<0.001 and 0.004, respectively). In multivariate logistic regression model, the exon 19 deletion was the only factor that predicted both a higher ORR (odds ratio 2.04, 95% CI 1.31--3.17, P = 0.002) and a higher DCR (odds ratio 2.40, 95% CI 1.21--4.77, P = 0.012). Gender and ECOG PS (0--1) remained significantly correlated with DCR in multivariate analysis (data not shown).

10.1371/journal.pone.0120852.t004

###### Univariate analysis of objective response rate and disease control rate in patients harboring *EGFR* mutations (n = 352).

![](pone.0120852.t004){#pone.0120852.t004g}

                                                   Patient No.   ORR (%)   P value[\*](#t004fn002){ref-type="table-fn"}   DCR (%)   P value[\*](#t004fn002){ref-type="table-fn"}
  ------------------------------------------------ ------------- --------- ---------------------------------------------- --------- ----------------------------------------------
  Age (yrs)                                                                0.449                                                    0.880
   ≤ 65                                            189           56.6                                                     85.2      
   \> 65                                           163           60.7                                                     85.9      
  Gender                                                                   0.147                                                    0.001
   Male                                            131           53.4                                                     77.1      
   Female                                          221           61.5                                                     90.5      
  Smoking                                                                  0.208                                                    0.013
   Non-smokers                                     266           60.5                                                     88.3      
   Current/former smokers                          86            52.3                                                     76.7      
  ECOG PS[^\#^](#t004fn003){ref-type="table-fn"}                           0.660                                                    \<0.001
   0--1                                            289           58.5                                                     88.6      
   ≥ 2                                             57            54.4                                                     68.4      
  Stage                                                                    0.564                                                    0.393
   IIIb                                            12            50.0                                                     75.0      
   IV                                              340           58.8                                                     85.9      
  Mutation types                                                           0.004                                                    0.004
   Exon 19 deletions                               157           68.2                                                     91.1      
   Exon 21 L858R                                   170           51.2                                                     82.9      
   Others                                          25            48.0                                                     68.0      
  EGFR-TKIs                                                                0.448                                                    0.142
   Gefitinib                                       336           58.0                                                     84.8      
   Erlotinib                                       16            68.8                                                     100       

EGFR, epidermal growth factor receptor; ORR, objective response rate; DCR, disease control rate; ECOG PS, ECOG PS, Eastern Cooperative Oncology Group performance status.

\*Mutation types by Pearson Chi-square test; otherwise by Fisher's exact test.

^\#^Exclude 6 cases with missing ECOG PS data.

The median PFS and OS were 11.6 (95% CI 10.0--13.2) and 39.4 (95% CI not applicable) months, respectively. In the univariate analysis, non-smokers and patients with ECOG PS 0--1 were associated with a significant longer PFS and ECOG PS (0--1) was the only factor that predicted a longer OS significantly (data not shown). Although patients harbored exon 19 deletions were associated with both a higher ORR and DCR, neither PFS (HR 0.74, 95% CI 0.55--1.00, P = 0.053) nor OS (HR 0.70, 95% CI 0.42--1.16, P = 0.163) was significantly correlated with *EGFR* mutation types in multivariate analysis. In multivariate Cox proportional hazard model, ECOG PS (0--1) was the only factor that independently predicted both a longer PFS (HR 0.67, 95% CI 0.46--0.97, P = 0.034) and OS (HR 0.46, 95% CI 0.27--0.79, P = 0.005).

Discussion {#sec016}
==========

The success of *EGFR* and *ALK* inhibitor therapies in lung cancer patients with *EGFR* mutations and *EML4-ALK* translocations initiated the era of targeted therapy in advanced NSCLC \[[@pone.0120852.ref005],[@pone.0120852.ref008]\] and shifted treatment from platinum-based chemotherapy to molecularly targeted therapy. Recent genomic studies in lung adenocarcinoma have identified other potential therapeutic targets, such as mutations in *KRAS*, *HER2* and *BRAF*, *ROS1* rearrangements, *RET* fusions and *MET* amplification \[[@pone.0120852.ref017],[@pone.0120852.ref018]\]. As the current trend of NSCLC treatment, especially lung adenocarcinoma, has been shifted from tumor stage-based to more individualized therapies based on histological and molecular characteristics \[[@pone.0120852.ref019]\], the increasing importance of genomic information should prompt physicians to obtain adequate tissue specimens when planning diagnostic procedures \[[@pone.0120852.ref020]\].

In East Asia, there are several unique characteristics of lung cancer \[[@pone.0120852.ref021]\], including the predominance of adenocarcinoma over other cell types and a large proportion of never smoker and female patients. Such features may provide keys to further investigate the treatment or prevention of lung cancer in East Asians. Moreover, the incidences of activating mutations of oncogenic drivers in Western and Asian populations are different, especially the *EGFR* and *KRAS* mutations \[[@pone.0120852.ref003],[@pone.0120852.ref018],[@pone.0120852.ref022],[@pone.0120852.ref023]\]. In the present study, we showed that the incidence of *EGFR* mutations in Taiwanese lung adenocarcinoma patients was 55.7%, which was similar to the results of PIONEER study \[[@pone.0120852.ref014]\]. *EGFR* mutation is the most important biomarker for predicting the outcome of EGFR-TKI therapy. In the present study, the ORR of EGFR-TKI therapy was 58.5%, which was slightly lower than that of randomized controlled trials. However, we also enrolled patients with poor ECOG PS (2 or more) and outcome with regard to DCR, PFS and OS was similar to previous studies \[[@pone.0120852.ref004],[@pone.0120852.ref005]\]. The incidence of *KRAS* mutation in the present study was only 5.0%, much lower than that reported in Caucasians and even lower than that in other Asian countries \[[@pone.0120852.ref018],[@pone.0120852.ref022]\]. Since there is a significant association between *KRAS* mutations and smoking behaviors \[[@pone.0120852.ref022],[@pone.0120852.ref024]\], the relatively high rate of non-smoking lung cancers in Taiwan might be one reason for the lower *KRAS* mutation rate in the present study. Herein, our results disclosed the higher *EGFR* mutation rate in female and non-smokers and higher *KRAS* mutation rate in male and smokers, which were in line with the results of previous studies \[[@pone.0120852.ref024],[@pone.0120852.ref025]\].

*KRAS* mutations in lung adenocarcinoma consist of single amino acid substitutions in hotspots located mostly in codon 12 and rarely in codons 13 and 61 \[[@pone.0120852.ref026],[@pone.0120852.ref027]\]. In our study, codon 12 and codon 13 mutations were detected, with much higher mutation rate in codon 12 than in codon 13 (95.7% vs. 4.3%). There is evidence that different *KRAS* mutant proteins have differing clinical significance. In previous study, either G12C or G12V-mutant *KRAS* predicted shorter progression free survival to EGFR-TKI compared to wild type or other *KRAS* mutations \[[@pone.0120852.ref028]\]. Despite the lack of effective *KRAS*-targeted agents currently, detection of *KRAS* mutations could be considered to apply in clinical practice for its prognostic value \[[@pone.0120852.ref029],[@pone.0120852.ref030]\].

The rate of *BRAF* V600E mutation was 0.7% (12/1772) in the present study with eight non-smokers and four smokers. In the study by An et al., *BRAF* mutation rate was 2.3% (7/307) in lung adenocarcinoma, while *BRAF* exon 15 mutation rate was 0.98% (3/307) \[[@pone.0120852.ref031]\]. The *BRAF* V600E mutation rate was similar to that in our study. Our results showed that there was no significant association of *BRAF* V600E mutation with patients' age, gender, smoking status or tumor stage. This differs from a recent meta-analysis by Chen et al. \[[@pone.0120852.ref032]\], showing that *BRAF* V600E mutation was significantly correlated with female gender and non-smoking history. Because different cohorts of patients and detection methods potentially confound the screening of uncommon mutations, further studies are needed to clarify the nature of *BRAF* mutations. Although *BRAF* mutations are uncommon, they represent an important therapeutic target due to the availability of individualized therapies in clinical use for melanoma and the promising results reported in ongoing clinical trials for NSCLC patients \[[@pone.0120852.ref033]\].

*HER2* mutations consist of in-frame insertions in exon 20, especially HER2YVMA mutant, leading to constitutive activation of the receptor and downstream *AKT* and *MEK* pathways \[[@pone.0120852.ref034]\]. *HER2* mutations meet the definition of genetic driver and the concept of transforming property of such a genetic alteration has been proved in preclinical models \[[@pone.0120852.ref035]\]. In the study by Mazieres et al., *HER2* mutation was identified in 65 (1.7%) of 3800 patients tested with a high proportion of women (69%) and never-smokers (52.3%) \[[@pone.0120852.ref036]\]. In our study, similar *HER2* mutation rate (2.0%) was found with a higher mutation rate in patients with advanced stage diseases. As several agents might be active in *HER2*-mutant lung adenocarcinoma, it is important to screen for *HER2* mutations for the potential efficacy of *HER2*-targeted medications.

*ALK* rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in NSCLC. The rate of *ALK* rearrangements ranged from 3 to 7% of unselected patients with NSCLC \[[@pone.0120852.ref037]--[@pone.0120852.ref039]\]. Similar to *EGFR* mutations, *ALK* rearrangements are associated with distinct clinical features, including younger age at diagnosis, never of light smokers and adenocarcinoma histology. Phase 3 study of crizotinib in previously treated patients with *ALK*-rearranged advanced NSCLC showed an ORR of 65% and a PFS of 7.7 months, which was significantly superior to the results with standard chemotherapy \[[@pone.0120852.ref008]\].

FISH analysis is the only approved diagnostic test to detect break-apart signals in *ALK* rearrangement. However, the apparatuses required for FISH analysis may not be available in all diagnostic laboratories. IHC can be an alternative to FISH and using the highly sensitive detection methods in combination with high affinity antibodies, IHC can effectively detect *ALK* fusion protein in lung adenocarcinoma with high sensitivity and specificity \[[@pone.0120852.ref040],[@pone.0120852.ref041]\]. Automated IHC assay system devised by Ventana was used in this study. Ying et al. assessed 196 lung adenocarcinomas using Ventana IHC, FISH, Cell Signaling Technology (CST) IHC and RT---PCR and the results showed that 65 (33%), 63 (32%), 70 (36%) and 69 (35%) cases were *ALK* positive, respectively \[[@pone.0120852.ref013]\]. The sensitivity and specificity of Ventana IHC were 100% and 98%. The automated Ventana IHC system is desirable to be considered as a guide to prescribe ALK inhibitors treatment, as IHC is a routine methodology in most pathology laboratories to detect a protein of interest. In the case of the availability of tumor tissues, our results may be slightly skewed due to the small sample size tested for *ALK* rearrangements.

In the present study, around 35% of lung adenocarcinoma patients did not have detectable oncogenic drivers. The comprehensive molecular profiling of 230 resected lung adenocarcinomas reported recently by Cancer Genome Atlas Research Network also showed that 24.4% of patients had no detectable driver oncogenic mutations at initial identification of candidate driver genes \[[@pone.0120852.ref017]\].

In summary, our study demonstrates that lung adenocarcinoma defined by specific driver gene alterations could be considered as different diseases. The identification of driver mutations has heralded a new era of targeted therapy in lung adenocarcinoma with currently available and potentially targetable genetic aberrations.
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